keyword
MENU ▼
Read by QxMD icon Read
search

Nabilone

keyword
https://www.readbyqxmd.com/read/29134767/availability-and-approval-of-cannabis-based-medicines-for-chronic-pain-management-and-palliative-supportive-care-in-europe-a-survey-of-the-status-in-the-chapters-of-the-european-pain-federation
#1
N Krcevski-Skvarc, C Wells, W Häuser
BACKGROUND: There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS: The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care...
November 13, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29017688/cannabinoids-in-pain-management-and-palliative-medicine
#2
Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke
BACKGROUND: There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. METHODS: We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, and Medline...
September 22, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28921814/nabilone-pharmacotherapy-for-cannabis-dependence-a-randomized-controlled-pilot-study
#3
Kevin P Hill, Matthew D Palastro, Staci A Gruber, Garrett M Fitzmaurice, Shelly F Greenfield, Scott E Lukas, Roger D Weiss
BACKGROUND AND OBJECTIVES: We assessed the safety, tolerability, and preliminary efficacy of nabilone, a cannabinoid agonist, to treat cannabis dependence. METHODS: Eighteen adults with DSM-IV cannabis dependence were randomized to receive either 2 mg/day of nabilone (n = 10) or placebo (n = 8) for 10 weeks in addition to medication management. Twelve participants, six in each group, completed treatment. The safety and tolerability of nabilone was assessed at each visit...
September 18, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/28861507/a-conversion-of-oral-cannabidiol-to-delta9-tetrahydrocannabinol-seems-not-to-occur-in-humans
#4
Gerhard Nahler, Franjo Grotenhermen, Antonio Waldo Zuardi, José A S Crippa
Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions, CBD can be transformed to delta9-tetrahydrocannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates significantly from physiological conditions in the stomach; therefore, SGF does not allow an extrapolation to in vivo conditions...
2017: Cannabis and Cannabinoid Research
https://www.readbyqxmd.com/read/28780725/a-review-of-oral-cannabinoids-and-medical-marijuana-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-a-focus-on-pharmacokinetic-variability-and-pharmacodynamics
#5
REVIEW
Melissa E Badowski
PURPOSE: Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond to conventional antiemetic therapy. The aim of this article is to provide an overview of the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of oral cannabinoids for patients with CINV...
August 5, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28655715/incretin-secretion-in-humans-is-under-the-influence-of-cannabinoid-receptors
#6
RANDOMIZED CONTROLLED TRIAL
Chee W Chia, Olga D Carlson, David D Liu, Isabel González-Mariscal, Sara Santa-Cruz Calvo, Josephine M Egan
The mechanisms regulating incretin secretion are not fully known. Human obesity is associated with altered incretin secretion and elevated endocannabinoid levels. Since cannabinoid receptors (CBRs) are expressed on incretin-secreting cells in rodents, we hypothesized that endocannabinoids are involved in the regulation of incretin secretion. We compared plasma glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) responses during oral glucose tolerance test (OGTT) in 20 lean and 20 obese participants from the Baltimore Longitudinal Study of Aging (BLSA)...
September 1, 2017: American Journal of Physiology. Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28537982/selective-cannabinoids-for-chronic-neuropathic-pain-a-systematic-review-and-meta-analysis
#7
REVIEW
Howard Meng, Bradley Johnston, Marina Englesakis, Dwight E Moulin, Anuj Bhatia
BACKGROUND: There is a lack of consensus on the role of selective cannabinoids for the treatment of neuropathic pain (NP). Guidelines from national and international pain societies have provided contradictory recommendations. The primary objective of this systematic review and meta-analysis (SR-MA) was to determine the analgesic efficacy and safety of selective cannabinoids compared to conventional management or placebo for chronic NP. METHODS: We reviewed randomized controlled trials that compared selective cannabinoids (dronabinol, nabilone, nabiximols) with conventional treatments (eg, pharmacotherapy, physical therapy, or a combination of these) or placebo in patients with chronic NP because patients with NP may be on any of these therapies or none if all standard treatments have failed to provide analgesia and or if these treatments have been associated with adverse effects...
November 2017: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/28370228/pharmacologic-treatment-of-cannabinoid-hyperemesis-syndrome-a-systematic-review
#8
REVIEW
John R Richards, Brent K Gordon, Aaron R Danielson, Aimee K Moulin
Cannabinoid hyperemesis syndrome (CHS) has become more prevalent with increasing cannabis use. CHS is often resistant to standard antiemetics. The objective of this study is to review the current evidence for pharmacologic treatment of CHS. Medline, PsycINFO, DARE, OpenGrey, Google Scholar, and the Cochrane Library were searched from inception to February 2017. Articles were selected and reviewed independently. Evidence was graded using Oxford Center for Evidence-Based Medicine guidelines. The search resulted in 1262 articles with 63 of them eligible for inclusion (205 human subjects)...
June 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28349316/cannabis-cannabinoids-and-sleep-a-review-of-the-literature
#9
REVIEW
Kimberly A Babson, James Sottile, Danielle Morabito
PURPOSE OF REVIEW: The current review aims to summarize the state of research on cannabis and sleep up to 2014 and to review in detail the literature on cannabis and specific sleep disorders from 2014 to the time of publication. RECENT FINDINGS: Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Delta-9 tetrahydrocannabinol (THC) may decrease sleep latency but could impair sleep quality long-term...
April 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/28281107/cannabis-for-pain-and-headaches-primer
#10
REVIEW
Philip S Kim, Michael A Fishman
PURPOSE OF REVIEW: Marijuana has been used both medicinally and recreationally since ancient times and interest in its compounds for pain relief has increased in recent years. The identification of our own intrinsic, endocannabinoid system has laid the foundation for further research. RECENT FINDINGS: Synthetic cannabinoids are being developed and synthesized from the marijuana plant such as dronabinol and nabilone. The US Food and Drug Administration approved the use of dronabinol and nabilone for chemotherapy-associated nausea and vomiting and HIV (Human Immunodeficiency Virus) wasting...
April 2017: Current Pain and Headache Reports
https://www.readbyqxmd.com/read/28276820/cannabinoids-for-treating-inflammatory-bowel-diseases-where-are-we-and-where-do-we-go
#11
REVIEW
Carina Hasenoehrl, Martin Storr, Rudolf Schicho
Fifty years after the discovery of Δ(9)-tetrahydrocannabinol (THC) as the psychoactive component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a potential treatment is given. From first surveys and small clinical studies in patients with IBD we have learned that Cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite. Single ingredients from Cannabis, such as THC and cannabidiol, commonly described as cannabinoids, are responsible for these effects...
April 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28245077/marijuana-and-other-cannabinoids-as-a-treatment-for-posttraumatic-stress-disorder-a-literature-review
#12
Maria M Steenkamp, Esther M Blessing, Isaac R Galatzer-Levy, Laura C Hollahan, William T Anderson
Posttraumatic stress disorder (PTSD) is common in the general population, yet there are limitations to the effectiveness, tolerability, and acceptability of available first-line interventions. We review the extant knowledge on the effects of marijuana and other cannabinoids on PTSD. Potential therapeutic effects of these agents may largely derive from actions on the endocannabinoid system and we review major animal and human findings in this area. Preclinical and clinical studies generally support the biological plausibility for cannabinoids' potential therapeutic effects, but underscore heterogeneity in outcomes depending on dose, chemotype, and individual variation...
March 2017: Depression and Anxiety
https://www.readbyqxmd.com/read/28235999/concise-review-of-the-management-of-iatrogenic-emesis-using-cannabinoids-emphasis-on-nabilone-for-chemotherapy-induced-nausea-and-vomiting
#13
REVIEW
Joseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, Gianpietro Zampogna, Robert B Raffa
Chemotherapy-induced nausea and vomiting (CINV) is a prevalent, distressing, and burdensome side effect of cancer chemotherapy. It is estimated to affect the majority of patients receiving certain anti-cancer drug regimens and can be treatment-limiting, even for life-saving medications. Despite seemingly numerous options, such as antimuscarinic anticholinergics, antihistamines, 5-HT3 receptor antagonists, dopamine receptor antagonists, and neurokinin-1 receptor antagonists, preventative therapies are often inadequately effective, particularly for "delayed CINV"-leaving an important unmet clinical need...
March 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28161834/cannabinoid-receptors-in-regulating-the-gi-tract-experimental-evidence-and-therapeutic-relevance
#14
REVIEW
Ulrike Taschler, Carina Hasenoehrl, Martin Storr, Rudolf Schicho
Cannabinoid receptors are fundamentally involved in all aspects of intestinal physiology, such as motility, secretion, and epithelial barrier function. They are part of a broader entity, the so-called endocannabinoid system which also includes their endocannabinoid ligands and the ligands' synthesizing/degrading enzymes. The system has a strong impact on the pathophysiology of the gastrointestinal tract and is believed to maintain homeostasis in the gut by controlling hypercontractility and by promoting regeneration after injury...
2017: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/28160217/a-randomized-controlled-trial-of-nabilone-for-the-prevention-of-acute-postoperative-nausea-and-vomiting-in-elective-surgery
#15
RANDOMIZED CONTROLLED TRIAL
David Neville Levin, Zachary Dulberg, An-Wen Chan, Gregory M T Hare, C David Mazer, Aaron Hong
PURPOSE: Nabilone is a synthetic cannabinoid with properties that make it an appealing candidate as a postoperative nausea and vomiting (PONV) prophylactic adjunct. Nabilone has proven clinical utility in chemotherapy-related nausea and vomiting but has not been adequately tested for PONV. The purpose of this study was to evaluate the effectiveness of a single dose of nabilone for the prevention of PONV. METHODS: This was a pragmatic single-centre randomized-controlled trial comparing oral nabilone vs placebo for the prevention of PONV...
April 2017: Canadian Journal of Anaesthesia, Journal Canadien D'anesthésie
https://www.readbyqxmd.com/read/28050136/a-user-s-guide-to-cannabinoid-therapies-in-oncology
#16
REVIEW
V Maida, P J Daeninck
"Cannabinoid" is the collective term for a group of chemical compounds that either are derived from the Cannabis plant, are synthetic analogues, or occur endogenously. Although cannabinoids interact mostly at the level of the currently recognized cannabinoid receptors, they might have cross reactivity, such as at opioid receptors. Patients with malignant disease represent a cohort within health care that have some of the greatest unmet needs despite the availability of a plethora of guideline-driven disease-modulating treatments and pain and symptom management options...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/27561138/a-systematic-review-of-the-evidence-for-medical-marijuana-in-psychiatric-indications
#17
REVIEW
Samuel T Wilkinson, Rajiv Radhakrishnan, Deepak Cyril D'Souza
OBJECTIVE: Marijuana has been approved for a number of psychiatric conditions in many states in the US including posttraumatic stress disorder (PTSD), agitation in Alzheimer's disease, and Tourette's disorder. In this systematic review, we examine the strength of evidence for the efficacy of marijuana and other cannabinoids for these psychiatric indications. DATA SOURCES: The literature (MEDLINE) was searched for studies published between January 1980 and March 2015 using search terms related to marijuana and other cannabinoids and the specific diagnosis...
August 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27435265/cannabinoids-inflammation-and-fibrosis
#18
REVIEW
Robert B Zurier, Sumner H Burstein
Cannabinoids apparently act on inflammation through mechanisms different from those of agents such as nonsteroidal anti-inflammatory drugs (NSAIDs). As a class, the cannabinoids are generally free from the adverse effects associated with NSAIDs. Their clinical development thus provides a new approach to treatment of diseases characterized by acute and chronic inflammation and fibrosis. A concise survey of the anti-inflammatory actions of the phytocannabinoids Δ(9)-tetrahydrocannabinol (THC), cannabidiol, cannabichromene, and cannabinol is presented...
November 2016: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/27428009/cannabinoids-for-fibromyalgia
#19
REVIEW
Brian Walitt, Petra Klose, Mary-Ann Fitzcharles, Tudor Phillips, Winfried Häuser
BACKGROUND: This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue affecting approximately 2% of the general population. People often report high disability levels and poor health-related quality of life (HRQoL). Drug therapy focuses on reducing key symptoms and disability, and improving HRQoL. Cannabis has been used for millennia to reduce pain and other somatic and psychological symptoms...
July 18, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27407130/cannabinoids-for-symptom-management-and-cancer-therapy-the-evidence
#20
REVIEW
Mellar P Davis
Cannabinoids bind not only to classical receptors (CB1 and CB2) but also to certain orphan receptors (GPR55 and GPR119), ion channels (transient receptor potential vanilloid), and peroxisome proliferator-activated receptors. Cannabinoids are known to modulate a multitude of monoamine receptors. Structurally, there are 3 groups of cannabinoids. Multiple studies, most of which are of moderate to low quality, demonstrate that tetrahydrocannabinol (THC) and oromucosal cannabinoid combinations of THC and cannabidiol (CBD) modestly reduce cancer pain...
July 2016: Journal of the National Comprehensive Cancer Network: JNCCN
keyword
keyword
97319
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"